| Patient | Pablo Neruda |
|---|---|
| Date of birth | 1959-07-12 |
| Identifiers | MRN HR-ML051-SYN; SSN (made up) 000-51-2976 |
| Document date | 2026-08-10 |
| Author | Marisol Fairweather-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Itchy rash for four days. [S]
Mr. Neruda, a 67-year-old man with metastatic hormone-sensitive prostate cancer on leuprolide and apalutamide, now in the third week of radiotherapy to the prostate, called the clinic and was seen the same day, with a professional Spanish interpreter. Four days ago an itchy red rash appeared on his chest and spread to his back and upper arms. He has taken apalutamide for eight weeks. He started no other new medicine, soap or detergent. He has no fever, sore mouth, sore or red eyes, blisters, peeling, swelling of the face, or joint pain. The skin over the radiotherapy field on his lower abdomen is not affected. The itch keeps him awake for part of the night, but he is still writing every morning. [S]
| Element | Detail |
|---|---|
| Onset | Four days ago, eight weeks after starting apalutamide |
| Location | Chest, back and upper arms; face, palms, soles and the radiotherapy field spared |
| Character | Red, flat and slightly raised spots joining into patches; itchy |
| Associated signs and symptoms | Denies fever, mouth or eye sores, blisters, peeling and facial swelling |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or chills; tiredness from radiotherapy, unchanged |
| Integumentary | Positive | Itchy rash on the trunk and upper arms; no blisters or peeling |
| Eyes | Negative | No redness, pain or discharge |
| Ears, nose, mouth, and throat | Negative | No mouth sores or sore throat |
| Musculoskeletal | Negative | No joint pain or swelling; no bone pain |
| Genitourinary | Positive | Urinary frequency during radiotherapy, as expected; no burning or blood |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-04-06 to 2026-07-13 | completed | S |
| Amlodipine 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-07-13 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain | Two tablets up to three times daily as needed | Oral route | 2026-06-01 to 2026-09-14 | completed | S |
| Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food | One tablet once daily | Oral route | 2026-06-15 | active | S |
| Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeks | One injection every twelve weeks | Intramuscular route | 2026-06-22 | active | S |
| Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-15 | active | S |
| Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivation | One injection every six months | Subcutaneous route | 2026-07-13 | active | S |
| Triamcinolone acetonide 0.1% cream, apply a thin layer to the rash twice daily for two weeks (not the face or groin) | Twice daily for two weeks | Topical route | 2026-08-10 to 2026-08-24 | completed | S |
| Cetirizine 10 mg oral tablet, one tablet daily for itch | One tablet daily | Oral route | 2026-08-10 to 2026-08-31 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-10 | Body height | 178 | cm | S |
| 2026-08-10 | Body weight | 93 | kg | S |
| 2026-08-10 | Body mass index (BMI) [Ratio] | 29.4 | kg/m2 | S |
| 2026-08-10 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-08-10 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-08-10 | Heart rate | 80 | /min | S |
| 2026-08-10 | Respiratory rate | 14 | /min | S |
| 2026-08-10 | Body temperature | 36.8 | Cel | S |
| 2026-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-10 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-08-10 | Eosinophils [#/volume] in Blood by Automated count | 0.3 | 10*3/uL | 0-0.5 10*3/uL | Normal | S |
| 2026-08-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.97 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-08-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 86 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 7-55 U/L | Normal | S |
| 2026-08-10 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 8-48 U/L | Normal | S |
Vital signs recorded on 2026-08-10; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, comfortable; temperature 36.8, blood pressure 136/82, pulse 80 |
| Skin | Blanching erythematous macules and papules, merging into patches, over the chest, abdomen above the radiotherapy field, back and upper arms, about 20 percent of body surface; no vesicles, bullae, target lesions, skin pain or Nikolsky sign; face, palms, soles and genitals clear |
| Eyes | Conjunctivae clear |
| Mouth | Mucosa moist and intact; no ulcers |
| Lymph nodes | No cervical, axillary or inguinal lymphadenopathy |
| Abdomen | Soft and non-tender; no liver enlargement |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmed | resolved | confirmed | R97.20 | S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer. |
| Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1971 | active | confirmed | C61 | S — Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read. |
| Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compression | active | confirmed | C79.51 | S — Synthetic metastatic sites. |
| Pelvic lymph node metastases: right external iliac and right obturator nodes | active | confirmed | C77.5 | S — Synthetic nodal disease. |
| Hormone-sensitive prostate cancer | active | confirmed | Z19.1 | S — Synthetic status in the modern episode. |
| Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognition | active | confirmed | Z79.899 | S — Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy. |
| Essential hypertension for five years, on amlodipine | active | confirmed | I10 | S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure. |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding at intake, addressed at the second visit. |
| Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis) | active | confirmed | M85.89 | S — Synthetic bone-health finding on the DXA before androgen deprivation. |
| Prediabetes (hemoglobin A1c 5.9%) | active | confirmed | R73.03 | S — Synthetic metabolic finding at intake, relevant to androgen deprivation. |
| Maculopapular drug rash from apalutamide, grade 2 (about 20 percent of body surface, trunk and upper arms), eight weeks into treatment; no mucosal involvement, blistering, fever, eosinophilia or liver involvement; settled on topical steroid and an antihistamine without stopping apalutamide | active | confirmed | L27.0 | S — Synthetic intercurrent problem at an unscheduled visit; a known effect of apalutamide, not a historical claim. |
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); ERLEADA (apalutamide) tablets: prescribing information (2026)
Follow-up: Nurse telephone call in three days, with a photograph of the rash through the patient portal if he wishes. Three-month review in five weeks. Same-day review for any of the warning signs. Next scheduled visit 2026-09-14: three-month review: PSA and testosterone, thyroid function, blood count and chemistry, glucose, radiotherapy effects, the rash, the second leuprolide injection, and plans for the year. [S]